Physician

Hyatt Degreen, D.O.

According to 2025 Medicare claims, Hyatt Degreen, D.O. (NPI: 1235345596) practices medical oncology in the Lancaster, PA market, with the plurality of this provider's patient population coming from Lancaster, PA. This provider's primary affiliated billing organization is LANCASTER CANCER CENTER LTD (NPI: 1891889721; TIN: 232174179) and primary practice location at 17602-4013.

Degreen's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 426 traditional Medicare patients, billed 222,380 HCPCS/CPT codes, and received $5,108,357 in Medicare payments. The top billing code was 80053 (Blood test, comprehensive group of blood chemicals). Part D data shows 2,742 prescription claims across 254 beneficiaries totaling $6,818,409 in drug costs, led by Imbruvica (Ibrutinib). DME data shows 195 claims. Open Payments data shows 59 records totaling $2,546. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,466,439 to $5,108,357. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $2,063,847 to $6,818,409. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $5,736 and ending at $2,340.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	320	169,756	$1,466,439
2016	351	209,633	$1,543,655
2017	381	227,316	$2,392,235
2018	373	228,947	$2,974,040
2019	370	194,359	$2,968,623
2020	368	250,049	$2,992,728
2021	377	201,535	$3,416,706
2022	394	222,296	$3,923,781
2023	430	223,348	$4,420,812
2024	426	222,380	$5,108,357

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	176	1,840	$2,063,847
2016	186	1,529	$1,437,202
2017	196	1,620	$2,118,625
2018	217	2,312	$3,435,719
2019	219	2,573	$4,132,117
2020	218	2,801	$5,477,719
2021	238	3,179	$4,951,225
2022	243	2,989	$4,496,347
2023	250	2,499	$4,612,968
2024	254	2,742	$6,818,409

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	13	$31,555
2016	N/R	N/R	N/R
2017	N/R	138	$5,736
2018	24	253	$9,354
2019	22	170	$5,922
2020	N/R	196	$9,838
2021	N/R	279	$12,280
2022	N/R	285	$9,760
2023	N/R	192	$21,067
2024	N/R	195	$4,741

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
80053	Blood test, comprehensive group of blood chemicals	352	1,665	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	362	2,134	$8
82977	Glutamyltransferase (liver enzyme) level	351	1,660	$7
36415	Insertion of needle into vein for collection of blood sample	365	2,319	$7
83615	Lactate dehydrogenase (enzyme) level	351	1,661	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	69	1,923	$1,053,780
Darzalex Faspro	Daratumumab-Hyaluronidase-Fihj	37	1,029	$499,021
Revlimid	Lenalidomide	31	833	$457,348
Calquence	Acalabrutinib Maleate	28	840	$412,520
Brukinsa	Zanubrutinib	27	810	$397,012

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	35	$1,107
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	12	$857
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	54	$665
J8999	Prescription drug, oral, chemotherapeutic, nos	N	N/R	13	$630
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	30	$565

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	59	$2,546	US Oncology Corporate, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Hyatt Degreen, D.O.?

Tedicare shows public-source Medicare data for Hyatt Degreen, D.O. (NPI 1235345596), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Hyatt Degreen, D.O. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Hyatt Degreen, D.O.?

Hyatt Degreen, D.O. is linked to LANCASTER CANCER CENTER LTD (billing NPI 1891889721) in the available physician profile data.

Does Hyatt Degreen, D.O. have Open Payments data?

Hyatt Degreen, D.O. has 59 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.